Secukinumab (AIN457) in the treatment of ankylosing spondylitis

摘要: ABSTRACTIntroduction: Ankylosing spondylitis (AS) is a chronic immune-mediated disease characterised by inflammation and new bone formation in the axial skeleton. Current therapeutic strategies include non-steroidal anti-inflammatory drugs, local glucocorticoids tumour necrosis factor inhibitors. However, an unmet need exists for more treatment options particularly patients who become unresponsive to and/or cannot tolerate these medications. Interleukin (IL)-17A, proinflammatory cytokine that plays crucial role pathogenesis of AS, has emerged as promising target search therapies. Recently, IL-17A inhibitor secukinumab demonstrated significant efficacy reducing signs symptoms AS.Areas covered: Inhibition represents novel approach management AS. Secukinumab selectively targets inhibits its interaction with IL-17 receptor, thus inhibiting release cytokines, chemokin...